Emergent and DiFusion Form Strategic Partnership to Take CleanFuze™ Antimicrobial Implants to Market

The CleanFuze technology self sterilizing properties and superior tissue adhesion benefits patients, surgeons and hospitals by reducing surgical site infections in orthopedic and spine surgery.

Austin, TX (PRWEB) July 31, 2013 -- Emergent Technologies, Inc., a leading innovation solutions company, and DiFusion Technologies, Inc., a pioneering orthobiologics company, announced today a strategic partnership in which Emergent will assist DiFusion in the launch of its proprietary suite of CleanFuze antimicrobial orthobiologic implants.

CleanFuze implants use DiFusion’s core technology, a novel biomaterial that resists infection and forms a direct and lasting connection with bone. This material uses Metallic Ions as Therapeutic Agents (MITA’s) to effect cellular signaling and both upstream and downstream cellular metabolic processes.

According the Centers for Disease Control and Prevention, hospital infections, including surgical site infections, are the fourth largest killer in the U.S., claiming more U.S. lives than AIDS, breast cancer and traffic accidents combined.

“DiFusion’s proven biofilm inhibition technology and strong patent position are a good fit for our Partner Solutions Model,” said Thomas Harlan, Chairman and CEO of Emergent Technologies. “Utilizing our model will help DiFusion accelerate successful market acceptance and deployment of its CleanFuze technology.”

Derrick Johns, DiFusion Founder and CEO commented, “We look forward to working with Emergent and leveraging the experience and expertise the company has developed over many years of successful technology commercialization and its numerous industry partnerships.”

DiFusion will launch its CleanFuze Xiphos™ spinal implant products in the European Union later this year and is actively seeking strategic distribution partners through its alliance with Emergent. Interested parties should contact Kris Looney at klooney(at)emergenttechnologies(dot)com.

“We are beginning to see stronger than average premarket demand in Europe for the CleanFuze Xiphos product,” said Johns, “and expect this to continue as we expand the CleanFuze platform to include antimicrobial wound care, scaffold carriers, bone growth and tissue regeneration.”

About Emergent Technologies, Inc.
Headquartered in Austin, Texas, Emergent Technologies, Inc. (Emergent) utilizes its innovation-based, partner driven model to identify, manage, develop and bring to market game-changing scientific discoveries. Emergent's diverse business and technical team along with its unique innovation process of transforming scientific breakthroughs into technology platforms with multiple applications, maximizes the value of promising ideas and underutilized intellectual properties without the risk associated with commercial development. Emergent applies its experience and expertise to provide investors, entrepreneurs, and industry partners access to innovative solutions to advance initiatives and protect and grow core businesses with novel, differentiating technology. For more information, visit the Emergent website www.emergenttechnologies.com.
About DiFusion Technologies, Inc.
Founded in 2008 in Austin, Texas, DiFusion Technologies, Inc. is a medical device company focused on reducing the rising incidence of surgical site infections in orthopedic and spine surgery through the development of a suite of patented antimicrobial orthobiologic polymeric implants. Initially focusing on the multi-billion dollar spinal implant market, the company has developed a technology with applicability across a variety of orthopedic segments using well characterized implants with benefits for the patient, surgeon, hospital and payer. For more information about DiFusion Technologies, visit www.difusiontech.com

Media Contact: Derrick Johns – djohns(at)difusiontech(dot)com
Contact Information
Cameron Mackie
Emergent Technologies, Inc.
512 263 3232

Online Web 2.0 Version
You can read the online version of this press release [here](#).

If you have any questions regarding information in these press releases please contact the company listed in the press release. Our complete disclaimer appears [here](#) - PRWeb ebooks - Another [online visibility tool from PRWeb](#).